688180 君实生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.345-14.720-19.689-27.454-27.404
总资产报酬率 ROA (%)-0.155-7.556-11.579-19.107-20.243
投入资产回报率 ROIC (%)-0.177-8.887-14.041-22.727-24.558

边际利润分析
销售毛利率 (%)79.76381.32878.92163.99665.304
营业利润率 (%)-3.936-40.004-68.717-163.551-183.414
息税前利润/营业总收入 (%)-0.273-38.344-69.686-170.296-189.759
净利润/营业总收入 (%)-5.979-40.401-70.836-168.759-177.784

收益指标分析
经营活动净收益/利润总额(%)358.30192.44393.36992.68098.964
价值变动净收益/利润总额(%)-284.1594.8095.2473.0181.913
营业外收支净额/利润总额(%)24.4562.3271.3801.3750.421

偿债能力分析
流动比率 (X)2.1391.6041.7182.2854.086
速动比率 (X)1.9341.3981.4832.0643.746
资产负债率 (%)56.96651.08744.98135.46122.153
带息债务/全部投入资本 (%)46.76836.75830.45318.73910.697
股东权益/带息债务 (%)101.118152.932214.602411.315819.634
股东权益/负债合计 (%)73.13595.332120.838177.791340.888
利息保障倍数 (X)-0.055-14.6779,401.88438.14234.070

营运能力分析
应收账款周转天数 (天)59.86073.21791.74586.422189.637
存货周转天数 (天)347.674446.650491.996378.341386.772